Medicilon’s drug safety evaluation service successfully passed the CFDA review again

Last week, Medicilon’s pre-clinical drug safety evaluation service passed the CFDA inspection again. This time, the two Shanghai biopharmaceutical companies that have long-term cooperation with Medicilon passed the inspection.

Medicilon has a quality management system for drug safety evaluation based on the internationally certified AAALAC quality standard and compliance with international and domestic GLP regulations.Since 2008, we have continued to meet international standards and completed high-quality GLP safety evaluation services, establishing a long-term brand effect. Medicilon can perform systematic evaluation services covering multiple toxicity endpoints and has internationally recognized pathology studies to support our safety evaluation studies.

It is reported that the newly expanded preclinical drug safety evaluation laboratory of Medicipuya Pharmaceutical Technology (Shanghai) Co., Ltd. has been put into use in the second half of 2015. Take the special safety research service recognized by customers as an example (referring to No. 21 data in general). The main service content includes ASA, PCA, hemolysis and irritation tests, etc. The schedule has been nearly 4 months ahead of schedule. Can fully meet customer needs. According to researchers from Puya’s scientific research department, customers only need to do tests based on their needs to determine whether they need to do listing controls. If you can provide product manuals, it is better to conduct experiments after communicating and evaluating with our scientific research department.

If you want to know more about Medicilon’s pre-clinical services, please call 021-58591500-8957 or email to marketing@medicilon.com for business consultation.